Highstreet Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Highstreet Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$321K	Buy	+2,982	New	+$312K	0.01%	436

Other funds holding NBIX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Highstreet Asset Management's NBIX Position: Q4 2019 in Review

Highstreet Asset Management opened a new position in Neurocrine Biosciences (NBIX) in Q4 2019: 2,982 shares worth $321K. The stake represents 0.01% of the portfolio and ranks #436 among its holdings.

392 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

Highstreet Asset Management held 2,982 shares of Neurocrine Biosciences worth $321K as of Q4 2019.
Neurocrine Biosciences was a new Highstreet Asset Management position in Q4 2019.
Neurocrine Biosciences made up 0.01% of Highstreet Asset Management's portfolio in Q4 2019, its #436 holding.
392 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Highstreet Asset Management's 13F filing for Q4 2019, filed 12 Feb 2020.